1. Home
  2. SNDX vs EXPI Comparison

SNDX vs EXPI Comparison

Compare SNDX & EXPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$22.19

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo eXp World Holdings Inc.

EXPI

eXp World Holdings Inc.

HOLD

Current Price

$6.90

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDX
EXPI
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2014
2010

Fundamental Metrics

Financial Performance
Metric
SNDX
EXPI
Price
$22.19
$6.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
1
Target Price
$80.23
$11.50
AVG Volume (30 Days)
1.1M
998.8K
Earning Date
05-25-2026
05-27-2026
Dividend Yield
N/A
2.87%
EPS Growth
11.56
N/A
EPS
N/A
N/A
Revenue
$172,352,000.00
$500,147,681.00
Revenue This Year
$619.64
$6.93
Revenue Next Year
$115.96
$7.02
P/E Ratio
N/A
N/A
Revenue Growth
627.84
220.39
52 Week Low
$8.59
$6.91
52 Week High
$22.73
$12.23

Technical Indicators

Market Signals
Indicator
SNDX
EXPI
Relative Strength Index (RSI) 61.76 21.52
Support Level $19.59 N/A
Resistance Level $22.33 $11.36
Average True Range (ATR) 1.02 0.34
MACD 0.13 -0.03
Stochastic Oscillator 87.03 8.66

Price Performance

Historical Comparison
SNDX
EXPI

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About EXPI eXp World Holdings Inc.

eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.

Share on Social Networks: